Tofogliflozin, a novel sodium–glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
- 17 September 2013
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 170 (3) , 519-531
Abstract
Background and Purpose: Although inhibition of renal sodium–glucose co‐transporter 2 (SGLT2) has a stable glucose‐lowering effect in patients with type 2 diabetes, the effect of SGLT2 inhibition on renal dysfunction in type 2 diabetes remains to be determined. To evaluate the renoprotective effect of SGLT2 inhibition more precisely, we compared the effects of tofogliflozin (a specific SGLT2 inhibitor) with those of losartan (an angiotensin II receptor antagonist) on renal function and beta‐cell function in db/db mice.Experimental Approach: The effects of 8‐week tofogliflozin or losartan treatment on renal and beta‐cell function were investigated in db/db mice by quantitative image analysis of glomerular size, mesangial matrix expansion and islet beta‐cell mass. Blood glucose, glycated Hb and insulin levels, along with urinary albumin and creatinine were measuredKey Results: Tofogliflozin suppressed plasma glucose and glycated Hb and preserved pancreatic beta‐cell mass and plasma insulin levels. No improvement of glycaemic conditions or insulin level was observed with losartan treatment. Although the urinary albumin/creatinine ratio of untreated db/db mice gradually increased from baseline, tofogliflozin or losartan treatment prevented this increase (by 50–70%). Tofogliflozin, but not losartan, attenuated glomerular hypertrophy. Neither tofogliflozin nor losartan altered matrix expansion.Conclusions and Implications: Long‐term inhibition of renal SGLT2 by tofogliflozin not only preserved pancreatic beta‐cell function, but also prevented kidney dysfunction in a mouse model of type 2 diabetes. These findings suggest that long‐term use of tofogliflozin in patients with type 2 diabetes may prevent progression of diabetic nephropathy.Keywords
This publication has 57 references indexed in Scilit:
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?PLOS ONE, 2013
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal ModelsPLOS ONE, 2012
- New Experimental Models of Diabetic Nephropathy in Mice Models of Type 2 Diabetes: Efforts to Replicate Human NephropathyExperimental Diabetes Research, 2012
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011
- TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activityBritish Journal of Pharmacology, 2011
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family membersDiabetes Therapy, 2010
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Cardiovascular and autonomic phenotype of db/db diabetic miceExperimental Physiology, 2009